Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585-Reference-Cited by-同舟云学术

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585

Published:2012-10-17 Issue:6 Volume:21 Page:643-652
ISSN:1018-4813
Container-title:European Journal of Human Genetics
language:en
Short-container-title:Eur J Hum Genet

Author:

Schreml Julia,Riessland Markus,Paterno Mario,Garbes Lutz,Roßbach Kristina,Ackermann Bastian,Krämer Jan,Somers Eilidh,Parson Simon H,Heller Raoul,Berkessel Albrecht,Sterner-Kock Anja,Wirth Brunhilde

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Genetics

Link

http://www.nature.com/articles/ejhg2012222.pdf

Reference69 articles.

1. Crawford TO, Pardo CA : The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996; 3: 97–110.

2. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B : Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358–368.

3. Thieme A, Mitulla B, Schulze F, Spiegler AW : Chronic childhood spinal muscular atrophy in Germany (West-Thuringen)--an epidemiological study. Hum Genet 1994; 93: 344–346.

4. Lefebvre S, Burglen L, Reboullet S et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–165.

5. Wirth B : An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15: 228–237.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What could be the function of the spinal muscular atrophy-causing protein SMN in macrophages?;Frontiers in Immunology;2024-05-28

2. Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor;EMBO Molecular Medicine;2024-02-27

3. Innovating spinal muscular atrophy models in the therapeutic era;Disease Models & Mechanisms;2023-09-01

4. Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy;Scientific Reports;2023-06-26

5. Biomarkers in 5q-associated spinal muscular atrophy—a narrative review;Journal of Neurology;2023-06-08